Objectives and Methods: High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Promising results have been reported with more intensive regimens but this strategy is not suitable for elderly or unfit patients. Rituximab in association with cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone (R-VNCOP-B) demonstrated high efficacy and manageable toxicity as first-line treatment for elderly aggressive non-Hodgkin lymphoma patients. Results and Conclusion: In this case study, we report the rapid improvement, long-lasting complete remission, and mild toxicity of R-VNCOP-B regimen in an elderly, triple-expressor HGBL patient, with aggressive disease and poor-risk profile.

Cencini, E., Fabbri, A., Schiattone, L., Gentili, F., Mazzei, M.A., Bocchia, M. (2018). Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. ACTA CLINICA BELGICA, 73(6), 408-412 [10.1080/17843286.2017.1412888].

Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma

Cencini, Emanuele
;
Gentili, Francesco;Mazzei, Maria Antonietta;Bocchia, Monica
Supervision
2018-01-01

Abstract

Objectives and Methods: High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Promising results have been reported with more intensive regimens but this strategy is not suitable for elderly or unfit patients. Rituximab in association with cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone (R-VNCOP-B) demonstrated high efficacy and manageable toxicity as first-line treatment for elderly aggressive non-Hodgkin lymphoma patients. Results and Conclusion: In this case study, we report the rapid improvement, long-lasting complete remission, and mild toxicity of R-VNCOP-B regimen in an elderly, triple-expressor HGBL patient, with aggressive disease and poor-risk profile.
Cencini, E., Fabbri, A., Schiattone, L., Gentili, F., Mazzei, M.A., Bocchia, M. (2018). Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. ACTA CLINICA BELGICA, 73(6), 408-412 [10.1080/17843286.2017.1412888].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1030455